RxDoctor Payments Data

Patrick Lau, MD

Family Medicine · Sacramento, CANPI 1447212212

Payments from drug & device makers

$10,496in general payments, 2019–2025

Across 559 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Pfizer$910
  • Lilly USA, LLC$902
  • Novo Nordisk$681
  • Johnson & Johnson$667
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$10,25598%
  • Education$2412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,496 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$99,924
Medicare patients
218
Services billed
1,713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol43$61,040
EliquisApixaban54$45,839
JardianceEmpagliflozin37$44,801
OzempicSemaglutide29$38,656
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$29,296
JanuviaSitagliptin Phosphate18$26,323
TrulicityDulaglutide11$12,768
SymbicortBudesonide/Formoterol Fumarate22$7,949
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen213$5,551
Atorvastatin Calcium361$4,445
Gabapentin116$3,594
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,242
Wixela InhubFluticasone Propion/Salmeterol23$2,867
Albuterol Sulfate HfaAlbuterol Sulfate87$2,857
Fentanyl26$2,084

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,235$98,28588 claims
PfizerEliquis$910$45,83954 claims
Boehringer IngelheimJardiance$597$44,80137 claims
Novo NordiskOzempic$681$38,65629 claims
MerckJanuvia$367$26,32318 claims
Lilly USA, LLCTrulicity$902$12,76811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →